BUSINESS

Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API

March 15, 2013
Eli Lilly Japan has filed a New Drug Application (NDA) for the phosphodiesterase type 5 inhibitor tadalafil, which is currently marketed as the erectile dysfunction (ED) drug Cialis and the pulmonary arterial hypertension (PAH) treatment Adcirca, for an expected indication…

To read the full story

BUSINESS

By Izuru Ando

While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…

By Philip Carrigan

As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…

The average gap between the NHI prices and market prices of listed medicines shrank in the latest survey conducted in…

Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…